AZmed vs Rayscape (2026)

AI Health Index verifiedAugust 4, 2026
Verdict

Two European plain radiograph companies pointed at different films. AZmed is trauma first, detecting fractures, joint effusions and dislocations, which is the highest volume plain radiograph reading in any emergency department and the one where a missed finding most reliably becomes a complaint. Rayscape is chest first, with a large findings set, longitudinal comparison across prior scans and lung nodule work on computed tomography, plus independent evaluation in a tuberculosis screening setting. They barely overlap clinically, so a department choosing between them is really choosing which reading burden to attack: the overnight trauma queue or the chest backlog. Whichever you pick, ask for performance on your own case mix rather than the aggregate figure, because prevalence changes the false positive burden more than sensitivity does.

The case for AZmed
  • It is built around trauma radiography specifically, covering fractures, joint effusions and dislocations, which is the highest volume and most error prone plain film reading in any emergency department.
  • Depth in one reading task is a different proposition from breadth across a findings list, and trauma is where a missed finding most often becomes a claim.
  • European clearance and deployment across emergency settings mean the product has been used under time pressure rather than in a reading room.
The case for Rayscape
  • Breadth on chest radiography is substantial with longitudinal comparison across prior scans, plus lung nodule work on computed tomography, so it reaches beyond a single body region.
  • Independent evaluation in a tuberculosis screening context is a harder test than a reader study, which is more external validation than most vendors at this size hold.
  • Both on premise and cloud integration are available, which matters where images must stay inside the institution.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AZmed and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact AZmed Rayscape
Primary category Radiology & Imaging AI Radiology & Imaging AI
Founded 2018 2019
Headquarters Paris, France Timisoara, Romania
Website azmed.co rayscape.ai
Attribute Matrix

Side by Side

Axis
A
AZmed
R
Rayscape
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

AZmed

The AI Health Index awards AZmed its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against Rayscape, AZmed grades higher on Clinical and Operational Evidence and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

Rayscape

The AI Health Index awards Rayscape its top capability grade on AI Centrality. Set against AZmed, Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

FAQ

Questions buyers ask

Should we choose AZmed or Rayscape?

On the axes where the AI Health Index separates them, AZmed grades higher on Clinical and Operational Evidence and FDA and Regulatory Status, and Rayscape grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Rayscape leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.

Where do AZmed and Rayscape differ most?

The widest separation the AI Health Index records between AZmed and Rayscape is on FDA and Regulatory Status, where AZmed grades A and Rayscape grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.

Where do AZmed and Rayscape grade the same?

The AI Health Index grades AZmed and Rayscape the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Disclosure

These read different studies for different purposes and are compared here because both are European plain radiograph vendors that a hospital might see in the same evaluation. The comparison should be run per body region and per finding rather than on aggregate claims, since a trauma product and a chest product share almost no performance surface. Neither publishes a security attestation or pricing.

For any radiograph AI, prevalence and case mix in your own population determine the false positive burden more than the published sensitivity does, and neither vendor publishes performance stratified that way.